Evidence map›Paper›PMID 31434821›Full record

ArticleInternal medicine (Tokyo, Japan)2019

Clinical Characterization of Definite Autoimmune Limbic Encephalitis: A 30-case Series.

Yuri Shojima, Kenya Nishioka, Masao Watanabe, Takayuki Jo, Keiko Tanaka, Hiroshi Takashima, Kazuyuki Noda, Yasuyuki Okuma, Takao Urabe, Kazumasa Yokoyama and 1 more

Open access · diamondAbstract readMulticenter Study
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Review
  3. Neuropsychological Performance in Autoimmune Limbic Encephalitis: Evidence from an Immunotherapy-Naïve Cohort.Archives of clinical neuropsychology : the official journal of the National Academy of Neuropsychologists · 2022
    Article
  4. Review
  5. Neuropsychiatric Disorders Due to Limbic Encephalitis: Immunologic Aspect.International journal of molecular sciences · 2020
    Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 1 country.

Yuri ShojimaDepartment of Neurology, Juntendo University School of Medicine, Japan.
Kenya NishiokaDepartment of Neurology, Juntendo University School of Medicine, Japan.
Masao WatanabeDepartment of Neurology, Juntendo University Urayasu Hospital, Japan.
Takayuki JoDepartment of Neurology, Juntendo Shizuoka Hospital, Japan.
Keiko TanakaDepartment of Cellular Neurobiology, Brain Research Institute, Niigata University, Japan.
Hiroshi TakashimaDepartment of Neurology and Geriatrics, Kagoshima University Graduate School of Medical and Dental Sciences, Japan.
Kazuyuki NodaDepartment of Neurology, Juntendo Shizuoka Hospital, Japan.
Yasuyuki OkumaDepartment of Neurology, Juntendo Shizuoka Hospital, Japan.
Takao UrabeDepartment of Neurology, Juntendo University Urayasu Hospital, Japan.
Kazumasa YokoyamaDepartment of Neurology, Juntendo University School of Medicine, Japan.
Nobutaka HattoriDepartment of Neurology, Juntendo University School of Medicine, Japan.
Juntendo University · JPJuntendo University Shizuoka Hospital · JPJuntendo University Urayasu Hospital · JPKagoshima University · JPNiigata University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective Limbic encephalitis (LE) is an inflammatory condition of the limbic system that has an acute or subacute onset. Several types of antibodies are related to the onset of LE, including anti-N-methyl D-aspartate receptor (NMDAR) antibodies and voltage-gated potassium channel (VGKC)-complex antibodies. However, the characteristics and prevalence of LE remain unclear, especially in Asian cohorts, due to the rarity. We aimed to survey their characteristics. Materials and Methods Data of 30 cases clinically defined as "definite autoimmune LE" (based on the standard criteria) were retrospectively collected. These patients were categorized into four subtypes: NMDAR (+) (n=8), VGKC (+) (n=2), antibodies related to paraneoplastic syndrome (n=2), and an antibody-negative group (uncategorized) (n=18). Results LE is rare in Japan, and affected only 30 of 16,759 hospital patients (0.2%) over a ten-year period. The NMDAR (+) group showed distinctive symptoms, while the other three groups had similar indications. Brain MRI indicated significant medial temporal lobe atrophy at one year follow up after discharge. The prevalence of cognitive dysfunction as a complication was 64% (9/14). First-line immunotherapy resulted in a good outcome. A drastic improvement was seen from 4.0±1.1 to 1.1+ on the modified Rankin Scale. A good treatment outcome was observed in all groups (NMDAR, VGKC, and uncategorized), suggesting the importance of an early clinical diagnosis and the early initiation of treatment. Furthermore, we reviewed 26 cases that were clinically diagnosed as definitive autoimmune LE in previous case reports. Conclusion Our findings show that the establishment of a clinical diagnosis based on the clinical criteria of definitive autoimmune LE is important for the initiation of immunotherapy.

Indexed as

AdultAge of OnsetAtrophyAutoantibodiesAutoimmune DiseasesChild, PreschoolCognitive DysfunctionFemaleHumansImmunotherapyJapanLimbic EncephalitisMagnetic Resonance ImagingMaleMiddle AgedParaneoplastic SyndromesAutoantibodiesPotassium Channels, Voltage-GatedReceptors, N-Methyl-D-Aspartateautoimmune limbic encephalitisimmunotherapyNMDARVGKC

Identifiers

PMID31434821
PMCPMC6928500
OpenAlexW2969410076

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.